Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease

Digestive and Liver Disease

Volumn 40, Issue 7, 2008, Pages 547-553

  Berni Canani, R ^a   Terrin, G ^a   Rapacciuolo, L ^a   Miele, E ^a   Siani, M C ^a   Puzone, C ^a   Cosenza, L ^a   Staiano, A ^a   Troncone, R ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Crohn's disease; Disease activity; Endoscopy; Microscopic inflammation; Ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN;

ADOLESCENT; ARTICLE; CHILD; CHILD CARE; CLINICAL EXAMINATION; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FECES ANALYSIS; FEMALE; GASTROINTESTINAL ENDOSCOPY; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RELIABILITY; REMISSION; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS;

ADOLESCENT; BIOLOGICAL MARKERS; BIOPSY; CHILD; CHILD, PRESCHOOL; COLITIS, ULCERATIVE; COLPOSCOPY; CROHN DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; HUMANS; INFANT; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 44949220187     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2008.01.017     Document Type: Article

References (32)

1. Escher J.C., Taminiau J.A., Nieuwenhuis E.E.S., Buller H.A., and Grand R.J. Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel Dis 9 (2003) 34-58
2. Hildebrand H., Finkel Y., Grahnquist L., Lindholm J., Ekbom A., and Askling J. Changing pattern of paediatric inflammatory bowel disease in northern Stockholm 1990-2001. Gut 52 (2003) 1432-1434
3. Kugathasan S., Judd R.H., Hoffmann R.G., Heikenen J., Telega G., Khan F., et al. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr 143 (2003) 525-531
4. Arnott I.D., Watts D., and Ghosh S. Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease?. Aliment Pharmacol Ther 16 (2002) 857-867
5. Berni Canani R., Terrin G., Borrelli O., Romano M.T., Manguso F., Coruzzo A., et al. Short and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn's disease. Dig Liver Dis 38 (2006) 381-387
6. Fefferman D.S., and Farrell R.J. Endoscopy in inflammatory bowel disease: indications, surveillance, and use in clinical practice. Clin Gastroenterol Hepatol 3 (2005) 11-24
7. Del Rosario M.A., Fitzgerald J.F., Siddiqui A.R., Chong S.K., Croffie J.M., and Gupta S.K. Clinical applications of technetium Tc 99m hexamethyl propylene amine oxime leukocyte scan in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 28 (1999) 63-70
8. 18F-FDG PET/CT. J Nucl Med 48 (2007) 1053-1059
9. Solem C.A., Loftus Jr. E.V., Tremaine W.J., Harmsen W.S., Zinsmeister A.R., and Sandborn W.J. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 11 (2005) 707-712
10. Karoui S., Ouerdiane S., Serghini M., Jommi T., Kallel L., Fekih M., et al. Correlation between levels of C-reactive protein and clinical activity in Crohn's disease. Dig Liv Dis 39 (2007) 1006-1010
11. Holmquist L., Ahrén C., and Fällström S.P. Clinical disease activity and inflammatory activity in the rectum in relation to mucosal inflammation assessed by colonoscopy. Acta Paediatr Scand 79 (1990) 527-534
12. Cellier C., Sahmoud T., Froguel E., Adenis A., Belaiche J., Bretagne J.F., et al., The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. Gut 35 (1994) 231-235
13. Berni Canani R., Rapacciuolo L., Romano M.T., Tanturri de Horatio L., Terrin G., Manguso F., et al. Diagnostic value of faecal calprotectin in pediatric gastroenterology clinical practice. Dig Liver Dis 36 (2004) 467-470
14. Berni Canani R., Tanturri de Horatio L., Terrin G., Romano M.T., Miele E., Staiano A., et al. The combined use of non-invasive tests is useful in the initial diagnostic approach to a child with suspected inflammatory bowel disease. J Pediatr Gastroenterol Nutr 42 (2006) 9-15
15. Bunn S.K., Bisset W.M., Main M.J.C., Gray E.S., Olson S., and Golden B.E. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 33 (2001) 14-21
16. von Roon A.C., Karamountzos L., Purkayastha S., Reese G.E., Darzi A.W., Teare J.P., et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 202 (2007) 803-813
17. Roseth A.G., Schmidt P.N., and Fagerhol M.K. Correlation between faecal excretion of Indium-111 labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 34 (1999) 50-54
18. Roseth A.G., Aadland E., Jahnsen J., and Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 58 (1997) 176-180
19. Roseth A.G., Aadland E., and Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 39 (2004) 1017-1020
20. Olafsdottir E., Aksnes L., Fluge G., and Berstad A. Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children. Acta Pediatr 91 (2002) 45-50
21. Bunn S.K., Bisset W.M., Main M.J.C., and Golden B.E. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 32 (2001) 171-177
22. Fagerberger U.L., Loof L., Lindholm J., Hansson L.O., and Finkel Y. Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 45 (2007) 414-420
23. Hyams J.S., Ferry G.D., Mandel F.S., Gryboski J.D., Kibort P.M., Kirschner B.S., et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 12 (1991) 439-447
24. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Br Med J 298 (1989) 82-86
25. Costa F., Mumolo M.G., Bellini M., Romano M.R., Ceccarelli L., Arpe P., et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis 35 (2003) 642-647
26. Saverymuttu S.H., Camilleri M., Rees H., Lavender J.P., Hodgson H.J.F., and Chadwick V.S. Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease: I. A comparison with colonscopy, histology, and fecal Indium 111- granulocyte excretion. Gastroenterology 90 (1986) 1121-1128
27. Turner D., Otley A.R., Mack D., Hyams J., de Bruijne J., Uusoue K., et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 133 (2007) 423-432
28. Konikoff M.R., and Denson L.A. Role of fecal calprotectin as biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis 12 (2006) 524-534
29. Zilberman L., Maharshak N., Arbel Y., Rogowski O., Rozenblat M., Shapira I., et al. Correlated expression of high-sensitivity C-reactive protein in relation to disease activity in inflammatory bowel disease: lack of differences between Crohn's disease and ulcerative colitis. Digestion 73 (2006) 205-209
30. Tibble J.A., Sigthorsson G., Bridger S., Fagerhol M.K., Bjarnason I., et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 119 (2000) 15-22
31. Shastri Y., Povse N., and Stein J. Comparative study of new bedside fecal calprotectin test with an established ELISA to assess intestinal inflammation in a prospective study. Gastroenterology 130 Suppl. 2 (2006) A200
32. Langhorst J., Elsenbruch S., Koelzer J., Rueffer A., Michalsen A., and Dobos G.J. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 102 (2007) 1-8